FMW Stock Overview
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Veru Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$0.34 |
| Beta | -0.20 |
| 1 Month Change | 60.69% |
| 3 Month Change | 183.16% |
| 1 Year Change | -0.90% |
| 3 Year Change | -84.98% |
| 5 Year Change | n/a |
| Change since IPO | -41.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| FMW | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | -11.4% | 1.5% | 2.0% |
| 1Y | -0.9% | -1.7% | 2.0% |
Return vs Industry: FMW exceeded the German Personal Products industry which returned -2.3% over the past year.
Return vs Market: FMW underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| FMW volatility | |
|---|---|
| FMW Average Weekly Movement | 22.0% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: FMW's share price has been volatile over the past 3 months.
Volatility Over Time: FMW's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 189 | Mitch Steiner | verupharma.com |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death.
Veru Inc. Fundamentals Summary
| FMW fundamental statistics | |
|---|---|
| Market cap | €165.57m |
| Earnings (TTM) | -€58.63m |
| Revenue (TTM) | €14.89m |
11.7x
P/S Ratio-3.0x
P/E RatioIs FMW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FMW income statement (TTM) | |
|---|---|
| Revenue | US$15.93m |
| Cost of Revenue | US$7.92m |
| Gross Profit | US$8.01m |
| Other Expenses | US$70.73m |
| Earnings | -US$62.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 50.31% |
| Net Profit Margin | -393.72% |
| Debt/Equity Ratio | 19.0% |
How did FMW perform over the long term?
See historical performance and comparison